Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.39 EUR
Change Today +0.006 / 1.57%
Volume 10.0K
CY9A On Other Exchanges
As of 5:20 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (CY9A) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - €1.29
52 Week Low
07/27/15 - €0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEMCELLS INC (CY9A)

stemcells inc (CY9A) Related Businessweek News

No Related Businessweek News Found

stemcells inc (CY9A) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (CY9A) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $789.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $607.5K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

stemcells inc (CY9A) Key Developments

StemCells Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration

StemCells Inc. announced that Dr. Stephen Huhn, its Vice President of Clinical Research and Chief Medical Officer, presented an overview of the Company's clinical translation efforts to date, including a summary of the safety and preliminary efficacy data from the Company's Phase I/II study investigating its proprietary HuCNS-SC cells (purified human neural stem cells) as a potential therapy for geographic atrophy, the most advanced form of dry age related macular degeneration (AMD). The summary was presented June 26, at 4:00 p.m. CEST, at the 2015 Annual Meeting of the International Society for Stem Cell Research (ISSCR) being held in Stockholm, Sweden. The Company's 15-patient, open-label, Phase I/II trial was designed to evaluate the safety and preliminary efficacy of sub-retinal HuCNS-SC cell transplantation in geographic atrophy (GA), the most advanced form of dry AMD. Multiple safety and efficacy assessments were incorporated into the study, including various assessments of visual function and measurements of disease status by direct retinal examination. The tests in the study included best-corrected visual acuity (BCVA), contrast sensitivity (CS), microperimetry for analysis of visual function, optical coherence tomography (OCT), and fundus autofluorescence (FAF) to measure the extent of the underlying geographic atrophy. The safety profile emerging from the Phase I/II study supports the recent initiation of the Company's Radiant Study, a Phase II controlled proof-of-concept trial. The BCVA and CS measurements for the majority of the patients in the study either improved or remained stable in the treated eye. OCT analysis showed increases in central subfield thickness and in macular volume in the treated eye relative to the untreated eye. The prospective analysis of both cohorts in the study showed GA growth rates in the study eye that were lower than those seen in the control eye, consistent with the previously reported interim findings for Cohort I alone. However, to further investigate the possible effect of the cells on GA and to inform future clinical development, the Company subsequently engaged a reading center to perform a separate post-hoc assessment. The separate assessments have revealed greater than anticipated variability in grading of the images. While the prospective analysis for both Cohorts continues to show a decrease in the rate of GA progression in the treated eye for the majority of the patients, the post-hoc analysis did not reveal a similar trend.

StemCells Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 11:45 AM

StemCells Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 11:45 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Martin M. McGlynn, Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc.

StemCells Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada

StemCells Inc. announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CY9A:GR €0.39 EUR +0.006

CY9A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.09 USD -0.02
Bioheart Inc $0.0070 USD +0.0018
Biorestorative Therapies Inc $9.50 USD -0.50
Cytori Therapeutics Inc $0.40 USD -0.0054
Opexa Therapeutics Inc $0.41 USD -0.035
View Industry Companies

Industry Analysis


Industry Average

Valuation CY9A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at